

The world is racing to find safe and effective vaccines against COVID-19. And when we do, these vaccines must be made available to everyone who needs them regardless of nationality or wealth. Not only is this morally right but it is also the fastest way to end the pandemic. So as world leaders line up to make deals for COVID-19 vaccines candidates we want to know: **did this deal move us closer to, or further from, an equitable outcome?**

The Vaccine Access Test provides a framework to answer this question by evaluating deals between companies and countries using three metrics:

- **Prioritized:** Is this deal aligned with global guidelines on prioritizing allocation among at-risk populations?
- **Phased:** Does this deal allow for phased delivery of doses to ensure initial-supply is not monopolized?
- **Published:** Is the contracting processes transparent from start to finish?

Each metric is worth up to 2 points with the potential for 6 points total. **Here is how this deal stacks up.**

## DEAL SUMMARY

**Parties:** AstraZeneca and South Africa

**Date:** January 7, 2021

**Terms of Agreement:** South Africa signed a deal with AstraZeneca for 1.5 million doses of the vaccine to inoculate the country's health workers. This is South Africa's first announcement of the purchase of a COVID-19 vaccine. The first 1 million doses will be delivered in January from the Serum Institute of India, followed by an additional 500,000 doses in February.

METRIC	SCORE	RATIONALE
<b>Prioritized</b> 	2	1.5m doses would cover under 2% of South Africa's population a 2-dose regimen, fulfilling the 3% initial allocation threshold and the threshold to prioritize the most vulnerable 20% population.
<b>Phased</b> 	2	This agreement phases the timing that doses are delivered with the first doses being delivered at the end of 2020. Ideally this will allow for other countries to benefit from the initial supply and tier delivery of subsequent supply as it becomes available.
<b>Published</b> 	0	South Africa has not listed details about the terms of deal and pricing online. AstraZeneca has not disclosed their pricing model.

**Total Score: 4 out of 6**

This deal provides flexibility to ensure the initial supply of vaccines isn't monopolized by one country.

South Africa should publish accessible and timely contracting data online that details the terms of the deal. AstraZeneca could also disclose a break-down of how they arrived at their unit price, and what it cost to produce the vaccine.

▲ Impeding Equity

Advancing Equity ▲